The estimated Net Worth of Global Strategic Fund Ii L.... is at least 38.4 百万$ dollars as of 13 May 2022. Global L owns over 131,650 units of Checkmate Pharmaceuticals stock worth over 22,637,265$ and over the last 4 years Global sold CMPI stock worth over 15,778,756$.
Sign up
Global L CMPI stock SEC Form 4 insiders trading
Global has made over 8 trades of the Checkmate Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Global sold 131,650 units of CMPI stock worth 1,375,743$ on 13 May 2022.
The largest trade Global's ever made was selling 547,734 units of Checkmate Pharmaceuticals stock on 19 April 2022 worth over 5,701,911$. On average, Global trades about 214,681 units every 80 days since 2020. As of 13 May 2022 Global still owns at least 2,155,930 units of Checkmate Pharmaceuticals stock.
You can see the complete history of Global L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Checkmate Pharmaceuticals
Over the last 4 years, insiders at Checkmate Pharmaceuticals have traded over 15,801,789$ worth of Checkmate Pharmaceuticals stock and bought 928,470 units worth 13,457,615$ . The most active insiders traders include Holdings A/S Novo、Global Strategic Fund Ii L....、Michael Powell. On average, Checkmate Pharmaceuticals executives and independent directors trade stock every 27 days with the average trade being worth of 1,077,132$. The most recent stock trade was executed by Global Strategic Fund Ii L.... on 13 May 2022, trading 131,650 units of CMPI stock currently worth 1,375,743$.
What does Checkmate Pharmaceuticals do?
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Checkmate Pharmaceuticals's logo look like?
Complete history of Global L stock trades at Checkmate Pharmaceuticals
Checkmate Pharmaceuticals executives and stock owners
Checkmate Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. James E. Wooldridge M.D.,
Chief Medical Officer -
Dr. Kleem Chaudhary Ph.D.,
Chief Bus. Officer -
Alan Fuhrman,
Interim CEO, Pres & Director -
Dr. Arthur M. Krieg,
Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director -
Katherine A. Eade,
Gen. Counsel -
Robert F. Dolski,
CFO & Principal Accounting Officer -
Arthur M Krieg,
Chief Scientific Officer -
Joy Yan,
Director -
Holdings A/S Novo,
10% owner -
Barry Labinger,
President and CEO -
Kleem Chaudhary,
Chief Business Officer -
Karen Brennan,
Chief Operating Officer -
Global Strategic Fund Ii L....,
-
Michael Sofinnova Venture P...,
-
Michael Powell,
Director -
Keith T. Flaherty,
Director -
Oren Isacoff,
Director -
Peter Colabuono,
Director -
Robert Dolski,
Chief Financial Officer -
Alan Fuhrman,
Director -
Jon Marc Wigginton,
Director -
Alan Bash,
Chief Executive Officer